Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 11/20 | 0.54 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.48 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | CDK7 | P50613 | 4/20 | 0.40 |
| ▸ | CDK9 | P50750 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15214952 | 0.79 | CDK9 (0.41) | ALKCDK7CDK9 | |
| SCHEMBL1070192 | 0.76 | CDK7 (0.38) | ALKCDK7CDK9 | |
| SCHEMBL1070526 | 0.75 | CDK7 (0.38) | ALKCDK7CDK9 | |
| SCHEMBL1491776 | 0.72 | ALK (0.46) | ALKCDK7CDK9 | |
| SCHEMBL1491839 | 0.72 | ALK (0.45) | ALKCDK7CDK9 | |
| SCHEMBL14158215 | 0.71 | KCNN3 (0.71) | KCNN3KCNN1KCNN2CDK2PDE10A | |
| SCHEMBL4318891 | 0.71 | PDE10A (0.49) | KCNN3KCNN1KCNN2CDK2PDE10A | |
| SCHEMBL1491793 | 0.69 | ALK (0.45) | ALKCDK7CDK9 | |
| SCHEMBL14158199 | 0.69 | PDE10A (0.61) | KCNN3KCNN1KCNN2PDE10ACDK7 | |
| SCHEMBL14866230 | 0.69 | ALK (0.55) | ALKCDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518931-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-08-27 | — | — | US | disclosed |
| US-8518931-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-08-27 | — | — | US | disclosed |
| US-8518931-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-08-27 | — | — | US | disclosed |
| US-20110190264-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190264-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190264-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| EP-2271645-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126514-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190264-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | ROS1, IGF1R, INSR | KCNN3 2508/4885KCNN1 2783/4885KCNN2 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.